Population pharmacokinetic–pharmacodynamic modelling of the relationship between testosterone and prostate specific antigen in patients with prostate cancer during treatment with leuprorelin-Reference-Cited by-同舟云学术

Population pharmacokinetic–pharmacodynamic modelling of the relationship between testosterone and prostate specific antigen in patients with prostate cancer during treatment with leuprorelin

Published:2019-04-03 Issue:6 Volume:85 Page:1247-1259
ISSN:0306-5251
Container-title:British Journal of Clinical Pharmacology
language:en
Short-container-title:Br J Clin Pharmacol

Author:

Snelder Nelleke¹^ORCID,Drenth Henk‐Jan¹,Riber Bergmann Kirsten¹,Wood Nolan David²,Hibberd Mark²,Scott Graham²

Affiliation:

1. LAP&P Consultants BV Leiden The Netherlands

2. Takeda Development Centre Europe Ltd London UK

Funder

Takeda Development Centre Europe Ltd.

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bcp.13891

Reference28 articles.

1. Intramuscular depot formulations of leuprolide acetate suppress testosterone levels below a 20 ng/dL threshold: a retrospective analysis of two Phase III studies

2. Reassessment of the definition of castrate levels of testosterone: implications for clinical decision making

3. Redefining Clinically Significant Castration Levels in Patients With Prostate Cancer Receiving Continuous Androgen Deprivation Therapy

4. Efficacy and safety of leuprorelin acetate 6‐month depot in prostate cancer patients: a Phase III, randomized, open‐label, parallel‐group, comparative study in Japan;Suzuki K;Jpn J Clin Oncol,2015

5. Variations of serum testosterone levels in prostate cancer patients under LH-releasing hormone therapy: an open question

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Population PK and Semimechanistic PK/PD Modeling and Simulation of Relugolix Effects on Testosterone Suppression in Men with Prostate Cancer;Clinical Pharmacology & Therapeutics;2022-10-18

2. In vivo degradation forms, anti-degradation strategies, and clinical applications of therapeutic peptides in non-infectious chronic diseases;European Journal of Pharmacology;2022-10

3. A population K-PD model analysis of long-term testosterone inhibition in prostate cancer patients undergoing intermittent androgen deprivation therapy;Journal of Pharmacokinetics and Pharmacodynamics;2021-02-04

4. The castration level of testosterone and hormonal resistance of prostate cancer in androgen deprivation therapy;Meditsinskiy sovet = Medical Council;2020-12-21